Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

Takayuki Yoshino,Maria Di Bartolomeo,Kanwal Pratap Singh Raghav,Toshiki Masuishi,Fotios Loupakis,Hisato Kawakami,Kensei Yamaguchi,Tomohiro Nishina,Zev A. Wainberg,Elena Elez,Javier Rodríguez,Marwan Fakih,Fortunato Ciardiello,Kapil Saxena,Kojiro Kobayashi,Emarjola Bako,Yasuyuki Okuda,Gerold Meinhardt,Axel Grothey,Salvatore Siena

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

2021

3505Background: T-DXd is an antibody–drug conjugate of a humanized anti-HER2 antibody bound to a topoisomerase I inhibitor by a cleavable linker. The primary analysis of DESTINY-CRC01 (DS8201-A-J20...

Keywords:

open label study
Topoisomerase-I Inhibitor
Medicine
cleavable linker
in patient
Colorectal cancer
Conjugate
Trastuzumab
Cancer research
Antibody

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations